

1
2 A Phase I trial of iLidcombe: Online treatment for young children who stutter

3
4 Fiona Ross^a, Mark Onslow^a, Mark Jones^b, Ross Menzies^a, Ann Packman^a, Susan O'Brian^a, Anna
5 Hearne^a, Robyn Lowe^a

6
7
8 ^aUniversity of Technology Sydney, Australian Stuttering Research Centre, New South Wales,
9 Australia

10 ^bBond University, Faculty of Health Sciences & Medicine, QLD, Australia

11
12
13 * Corresponding Author: Mark Onslow, Australian Stuttering Research Centre, University of

14 Technology Sydney, Building 1, 15 Broadway, Ultimo, NSW, 2007, AUSTRALIA

15 e-mail: Mark.Onslow@uts.edu.au

16
17
18 *Keywords:* stuttering, children, Lidcombe Program, eHealth, online, treatment, telepractice

19
20 **Declaration of Interest Statement**

21 The author reports no conflict of interest.

Abstract

24

25

Aim. The aim of this Phase I trial was to assess the safety, compliance, and potential efficacy of iLidcombe: a standalone internet version of the Lidcombe Program for young children who stutter.

26

27

Method. We used a prospective single-group design involving 6 months of access to iLidcombe. Assessments occurred pre-treatment and after 6 months of access. Participants were 20 parents of young children who stuttered.

28

29

30

Results. There was evidence of stuttering severity reduction after using iLidcombe for 6 months. Compliance with the program was favourable, and there was no suggestion of any psychologically adverse impact on children.

31

32

33

Conclusions. The results of this Phase I trial provide a roadmap for further Phase II–IV clinical trial development.

34

35

36 *The impact of stuttering*

37 Stuttering onset typically occurs during early childhood in children 2 years of age (Ambrose &
38 Yairi, 1999), at a median of 31 months (Reilly et al., 2013). Around two-thirds to three-quarters of
39 children will recover at some later time because of treatment and/or natural recovery. However,
40 little of that recovery—below 10%—occurs within 18 months post onset (for a review, see Onslow,
41 2025). Quality-of-life impact of the condition is in a similar range to that for diabetes,
42 cardiovascular disease, and HIV (Norman et al., 2023). Quality-of-life issues commence soon after
43 onset (Briley et al., 2019; McAllister, 2016; Norman et al., 2023; Tığrak et al., 2020). Compared
44 with their peers, 7–12-year-old children who stutter develop social anxiety disorder five times more
45 often (Bernard et al., 2022; Iverach, et al., 2016). School children who stutter are more likely to
46 repeat a grade and have poorer academic outcomes than peers (Berchiatti et al., 2020; Boyle et al.,
47 1994; O’Brian et al, 2011; Williams et al., 1969). Indirect costs of stuttering later in life are social,
48 involving failure to attain full occupational potential (Boyce et al., 2022; Gerlach et al., 2018;
49 Jacobs et al., 2025; Lake et al., 2009; McAllister et al., 2012) and discrimination in the workplace
50 (Boyle & Cheyne, 2024; Gerlach et al. 2018). Direct costs of the condition are considerable.
51 Norman et al (2023) showed that willingness to pay for effective treatment can be 2–4 times the
52 annual family income, and 61% of families report a financial strain because of an adolescent who
53 stutters.

54 *The need for early stuttering intervention*

55 The potential lifelong effects of the condition may have prompted speech-language pathologists
56 (SLPs) from 10 countries ($N = 264$) to rank childhood stuttering as a priority on their waiting lists
57 for receiving treatment. Those SLPs had long waiting lists, on which they gave top priority to
58 children with feeding difficulties, with children who stutter as the next priority (McGill et al.,
59 2021). Eighteen Australian SLPs produced a consistent view (Erickson et al., 2022) by indicating
60 that stuttering is “more debilitating than other communication disorders with the potential for long-

61 term consequences to be more significant for clients” (p. 5). Participants at a conference with
62 clinicians and researchers from 29 countries indicated that “current evidence ... clearly tells us the
63 risks of early stuttering are certain and that they can be serious and potentially lifelong” (Lowe et
64 al., 2021, p. 9).

65 *The Lidcombe Program*

66 The Lidcombe Program, developed by the Australian Stuttering Research Centre and colleagues,
67 is one of many early stuttering interventions. A Cochrane Review found the program to have a large
68 effect size with evidence of effects beyond natural recovery (Sjøstrand, et al., 2021). Initially, the
69 SLP works with parents to individualize the treatment. Treatment involves parents giving feedback
70 about their children’s speech during enjoyable daily practice sessions and during everyday
71 conversations. Parents give intermittent feedback for stuttering moments, with the bulk of the
72 feedback being for stutter-free speech. The program does not target changes to the home
73 environment or target altering the child’s speech pattern in any way. It consists of two stages.
74 During Stage 1, the SLP and parent work together with a target of attaining no stuttering or nearly
75 no stuttering. During Stage 2, treatment is gradually withdrawn while maintaining no stuttering or
76 nearly no stuttering (Onslow et al., 2025). Progression through the Lidcombe Program is based on
77 parent reports of their children’s stuttering severity.

78 *Barriers to accessing the Lidcombe Program*

79 There are global barriers to Lidcombe Program access. The prevalence of early stuttering is
80 around 10% (Månsson, 2000; Reilly et al., 2013; Yairi, 1983), which is challenging for the SLP
81 workforce globally. Governments recognize that SLP workforces are not equipped to deal
82 adequately with such a prevalent condition (I CAN, & Royal College of Speech and Language
83 Therapists, 2018; Senate Community Affairs Committee Secretariat, 2014). A recent analysis of the
84 United States Early Childhood Longitudinal Study database indicated that 75% of children who
85 stuttered did not receive treatment (Briley & Jacobs, 2025). Caldera et al. (2023) reported that the

A PHASE I TRIAL OF iLIDCOMBE

86 United Kingdom and Australia have, respectively, 35.9 and 23.7 SLPs per 100,000 of population.
87 However, most children reside in countries where the SLP profession is not as well resourced:
88 Caldera et al. figures for India, Malaysia, and Sri Lanka are 0.17, 0.95, and 0.44 per 100,000
89 respectively. Those access issues are compounded by only 55% of the world's population living in
90 urban areas (United Nations, 2018), where SLP services are the most accessible.

91 *iLidcombe*

92 iLidcombe is an online eHealth adaptation of the Lidcombe Program that requires no SLP. It
93 adapts the work by Van Eerdenbrugh et al. (2016), who established that parents can be trained in
94 the Lidcombe Program treatment procedures with an online eHealth treatment. As with the
95 Lidcombe Program, iLidcombe treatment is administered by parents. It is based on previous
96 eHealth programs for stuttering (Erickson et al., 2012, 2016; Gunn, et al. 2019; Helgadóttir et al.,
97 2009; Menzies et al., 2016; Van Eerdenbrugh et al., 2016) developed by researchers at the
98 Australian Stuttering Research Centre and colleagues.

99 iLidcombe was developed to reflect the treatment process of the face-to-face Lidcombe Program.
100 Hence, the program features the voice of an SLP presenting information that supplements respective
101 pages of content. Pages include written information, diagrams, pictures, and video examples of
102 treatment procedures. The purpose of the SLP voice is to simulate a real clinical interaction between
103 an SLP and parent, where the SLP guides the treatment, providing instructions, explanations, and
104 encouragement. On each page of iLidcombe there is a "Feeling Sad?" button. If clicked, it displayed
105 the following text, with a link to local clinical psychology services: "If you are feeling
106 overwhelmed by doing this program, or you believe that you are becoming depressed, we strongly
107 encourage you to contact a clinical psychologist or medical practitioner in your area" As with the
108 Lidcombe Program, iLidcombe consists of two stages, described below.

109 *Stage 1*

A PHASE I TRIAL OF iLIDCOMBE

110 Stage 1 comprises 18 modules and weekly logins that continue until the child’s severity ratings
111 have reached criterion levels of no stuttering or nearly no stuttering. *Module 1* provides an overview
112 of the essential components of iLidcombe. *Modules 2–6* focus on stuttering measurement. Parents
113 are taught what stuttering is and how to identify moments of stuttering in childhood speech. They
114 are then introduced to the Lidcombe Program severity rating scale (0 = *no stuttering*, 1 = *extremely*
115 *mild stuttering*, 10 = *extremely mild stuttering*) and how to use the inbuilt daily severity rating tool.
116 *Modules 7–10* explain the structure and function of practice sessions, and parents are given
117 examples of suitable activities to use and taught how to structure conversations during these
118 activities. *Modules 11–12* focus on how verbal feedback for stutter-free speech should be given. In
119 *Modules 13–15*, video examples illustrate the three components of a practice session: the activity,
120 the structure of the conversation, and the feedback. Practical considerations for implementing the
121 daily treatment are highlighted, and parents are requested to trial a practice session with their child,
122 giving feedback for stutter-free speech.

123 Logins begin during *Modules 16–18* after *Modules 1–15* have been completed. The program
124 recommends that a consultation is completed each week. Parents can either log in to iLidcombe
125 daily to add severity ratings, or upload ratings for the entire week during their weekly consultation.
126 During these logins, parents are asked to answer a range of yes/no questions. These questions relate
127 to aspects of the treatment with their child, such as whether the child is enjoying treatment,
128 frequency of practice sessions, and type and frequency of feedback. After each consultation, parent
129 answers to these questions are used to generate a set of individualized recommendations and to
130 determine if further modules will be unlocked. Examples are: “Is your child happy to participate in
131 the practice sessions?” “Is your child comfortable with the feedback for smooth speech?” and “Are
132 you confident that you are rating your child’s stuttering severity accurately?”

133 *Modules 16–18* present information about parent feedback for stuttering during practice sessions,
134 feedback for stutter-free speech in everyday conversations, and feedback for stuttering in everyday
135 conversations. In addition to generating recommendations for how the parent should do the

A PHASE I TRIAL OF iLIDCOMBE

136 treatment, the consultation questions also ensure that the parent only progresses with iLidcombe if
137 the child is enjoying the treatment and the parent is feeling confident about administering it. If this
138 is not the case, additional modules remain locked and iLidcombe refers the parent to in-person SLP
139 services.

140 *Stage 2*

141 As with the Lidcombe Program, progression through iLidcombe is based on parent severity
142 ratings. Criteria for admission to Stage 2 reflect the in-person Lidcombe Program: parent severity
143 ratings of 0–1 for three consecutive weeks. As with the Lidcombe Program, Stage 2 of iLidcombe is
144 designed to maintain treatment gains while gradually withdrawing logins. Stage 2 logins consist of
145 two parts. The first requires parents to enter severity ratings. Based on those scores, iLidcombe
146 determines the time between logins. During the second part of the consultation, the program
147 provides recommendations to parents based on their answers to several questions and the severity
148 ratings entered. Email reminders are sent to parents to prompt them to log in for the prescribed
149 Stage 2 “consultations.” The time between logins increases if the program criteria are met. If
150 program criteria are not met, the parent is directed back to a previous step in Stage 2. If this occurs
151 for three consecutive occasions, iLidcombe sends a recommendation to discontinue using the
152 program and seek consultation from in-person SLP services.

153 User testing

154 Prior to the Phase I clinical trial reported here, iLidcombe was user tested with three cycles of
155 standard iterative methods (Currie et al., 2010; Obigbesan et al. 2024; Thornton et al., 2021) that the
156 team has used previously (Alateras et al., 2025). These cycles involve a think-aloud interview
157 method and structured surveys. The end users in these cycles were six SLPs with experience
158 working with children, and 10 parents of young children who stuttered. Based on user feedback,
159 iLidcombe was modified to improve ease of navigation, clarity, acceptability, and efficiency.

160 **Method**

161 *Aim*

162 The aim of this Phase I trial was to assess the safety, compliance, and potential efficacy of
163 iLidcombe. The trial was approved by the University of Technology Sydney Human Research
164 Ethics Committee ETH22-7772. All participants gave informed consent before taking part.

165 *Design*

166 We used a prospective single-group design involving 6 months of access to iLidcombe. The 6-
167 month study period was considered sufficient to assess safety and compliance and to detect any
168 signs of treatment response. Assessments occurred pre-treatment and after 6 months of access.

169 *Participants*

170 Participants were 20 parents of children who stuttered. Inclusion criteria were as follows: (a)
171 child 3–7 years of age, (b) a video recording of the child showing identifiable stuttering, (c) the
172 family located in Australia, (d) family access to an internet connection, and (e) parents with
173 functional English for reading and understanding the information provided in iLidcombe. Exclusion
174 criteria were as follows: (a) the child receiving any clinical interventions for stuttering at the time of
175 recruitment, and (b) the parent having been previously trained in any way to use Lidcombe Program
176 procedures.

177 *Safety screening*

178 Child wellbeing was monitored each week with a safety screening survey to identify any
179 children who might need to be withdrawn from the study. Parents were asked to respond “yes” or
180 “no” to nine statements about their child’s behavior for the prior week, as shown in Table 1.

181

182

INSERT TABLE 1 ABOUT HERE

183

184 If the answer was “yes” for any statement from the survey, the parent was then asked to
185 complete the Child Behaviour Checklist (Achenbach & Rescorla, 2001). This checklist assesses
186 child emotional and behavioral functioning. A raw total score between 0 and 51 is within the usual
187 range. If scores were above 51, the parent was interviewed in a video conference by two team
188 members (a clinical psychologist and an SLP) to determine if the changes in the child’s behavior
189 might be attributable to iLidcombe. If the answer “yes” was given for questions 1, 4, or 7 of the
190 safety screening survey, the parent was interviewed regardless of Child Behaviour Checklist scores.

191 *Stuttering severity and parent satisfaction with the child’s communication*

192 At pre-treatment and 6 months later, stuttering severity was measured by parent report of the
193 child’s typical stuttering severity for the previous week. At those times, parents also reported their
194 satisfaction with the child’s communication in everyday speaking situations using an adaptation of
195 the Karimi et al. (2018) 9-point scale, where 1 = *extremely dissatisfied* and 9 = *extremely satisfied*.

196 *6-month survey*

197 After 6 months, access to the program ceased. All parents were sent a survey that requested the
198 following information: (a) whether the child received treatment for stuttering from anywhere other
199 than the iLidcombe program during the 6-month trial period, (b) how likely the parent would be to
200 seek further professional help for their child’s stuttering with the next 12 months, and (c) how likely
201 the parent would be to seek professional help for any problems associated with their child’s
202 stuttering (for example, anxiety or social withdrawal) within the next 12 months. Parents responded
203 using the scale *very unlikely, unlikely, neutral, likely, and very likely*.

204 The survey also assessed parent satisfaction with iLidcombe by asking (a) what they liked and
205 disliked about it, (b) what aspects they found helpful or unhelpful, (c) whether they did the
206 treatment as recommended by the program, (d) whether they completed the daily practice tasks as
207 recommended by the program, (e) whether the program provided enough information and guidance,
208 (f) whether the program provided enough information to problem-solve when needed, and (g) how

209 easy or difficult it was to remain motivated to continue with iLidcombe. Parents selected from a
210 checklist of options and also typed responses in free-field text boxes (see appendix for a copy of the
211 survey).

212 **Results**

213 The flow chart of the trial is presented in Figure 1. Thirty-six parents expressed interest in the
214 trial, but 16 were excluded as ineligible because they did not meet the inclusion criteria (see
215 “Participants”). Twenty parents were recruited, but five withdrew from the trial 10–16 weeks after
216 gaining access to iLidcombe. Their reported reasons were that the child was no longer stuttering,
217 family illness, being offered treatment elsewhere, recent birth in the family and subsequent
218 relocation, and a doctor advising the parent that stuttering would resolve without treatment. The 15
219 children remaining in the study were of ages between 3 years 2 months to 7 years 10 months at
220 recruitment (mean 4 years 5 months). Nine were boys and six were girls.

221

222 INSERT FIGURE 1 ABOUT HERE

223

224 *Safety*

225 No safety issues emerged that required any participant to be withdrawn from the study. Eleven
226 participants answered “yes” to a statement on the safety survey and consequently completed the
227 Child Behaviour Checklist. No participants scored over 51 to trigger an interview. However, eight
228 participants responded “yes” to question 1, 4, or 7 and were consequently interviewed by the
229 clinical psychologist and SLP. Interviews revealed that there was no reason to believe that the “yes”
230 responses were related to iLidcombe treatment.

231 *Compliance*

232 Twenty parents commenced the trial, but five withdrew before completing 6 months of
233 treatment. Fourteen of the 20 parents completed *Modules 1–15*. Of the six parents who did not
234 complete *Modules 1–15*, five remained in the trial for the entire 6 months. Of the 14 parents who
235 did complete *Modules 1–15*, four were from the five parents who withdrew from the trial prior to
236 completing 6 months of treatment. Two of these 14 parents completed *Modules 1–15* within 2
237 weeks of gaining access to iLidcombe, a total of eight completed them within 5 weeks, and all 14
238 parents completed them within 10 weeks. Seven parents unlocked and completed *Module 16* four to
239 14 weeks after gaining access to iLidcombe. Six of these seven parents progressed and completed
240 *Module 17*, and one of these progressed to complete *Module 18*. Only one parent progressed to
241 Stage 2 after 19 weeks of access to the program.

242 *Potential efficacy*

243 Nine of the 15 parents who remained in the trial provided both pre-treatment and 6-month data.
244 For each of these nine participants, there was evidence of a reduction of typical stuttering severity
245 after 6 months access to iLidcombe (see Figure 2).

246

247 INSERT FIGURE 2 ABOUT HERE

248

249 For eight of the nine participants, there was also evidence of improved parent satisfaction with
250 the child's communication in everyday speaking situations after 6 months access to iLidcombe (see
251 Figure 3).

252

253 INSERT FIGURE 3 ABOUT HERE

254

A PHASE I TRIAL OF iLIDCOMBE

255 *iLidcombe evaluation survey*

256 The iLidcombe evaluation survey (see Appendix) was sent to all participating parents 6 months
257 after commencing the trial, including those who withdrew from the trial. Ten participants in total
258 completed the survey: nine who had completed the trial and one who had withdrawn. The majority
259 of them (seven of 10) indicated that the program helped to reduce their child’s stuttering: four
260 indicated “a lot” and three indicated “a moderate amount”. All ten parents indicated that they would
261 recommend it to other parents with children who stutter. Most parents (nine of 10) indicated that the
262 program gave them enough information and guidance to keep doing the treatment: seven responded
263 “yes” and two responded “mostly”.

264 No parent reported seeking treatment for the child’s stuttering while accessing iLidcombe. Two
265 parents indicated they were “very unlikely” to seek professional support for their child’s stuttering
266 after 6 months access to iLidcombe, three indicated they were “unlikely”, and two were “neutral”.
267 One parent reported being “likely”, and one was “very likely” to seek professional support after 6
268 months access to iLidcombe. Five parents indicated they would be “very unlikely” to seek
269 professional support for any problems associated with their child’s stuttering within the next 12
270 months, three indicated “unlikely”, and one indicated “very likely”. Almost all parents indicated that
271 they liked aspects of iLidcombe. These included nine parents who indicated they appreciated that a
272 specialist team developed the treatment and nine who indicated they liked the convenience of
273 learning how to do the treatment in their own time. Eight indicated that they liked being able to use
274 the treatment for self-determined periods without having to travel, and that there was no cost. In the
275 free-field text box one parent wrote: “Could do together with partner who would not have been able
276 to manage with work. Helped to be on the same page and share the load of treatment”.

277 Nine parents reported they found it helpful that the iLidcombe SLP explained treatment
278 procedures, and eight reported it helpful to read about the treatment procedures and watch videos of
279 other parents doing treatment. Six parents indicated that it was helpful to enter severity ratings and

280 see trends in the graph. Five found answering the yes/no questions during the logins and receiving
281 recommendations helpful. One parent wrote “Incredible program. We are so grateful for the
282 opportunity”. None of the parents indicated that reading or hearing about treatment procedures or
283 entering the severity ratings unhelpful. One parent wrote “I thought it was all great”, another wrote
284 “We didn’t find anything unhelpful. It was a great program!”

285 Some parents indicated that there were aspects of iLidcombe they disliked. Four indicated that
286 there was no opportunity for their child to develop clinical rapport with an SLP or to discuss any
287 difficulties they were having with the treatment. Three parents indicated there was no positive or
288 encouraging feedback from a live SLP. No parent indicated that they disliked the absence of
289 treatment demonstration by a live SLP. One parent indicated disliking the limited opportunity for
290 the program to adapt the treatment to their child’s individual needs. That parent wrote “I thought it
291 could have been helpful to have an opportunity to provide a comment on how I was feeling about
292 the treatment to get specific feedback on e.g his stutter was a lot worse on returning to school after
293 being off sick, I wondered if I should have changed anything”[sic]. Two parents reported that they
294 found answering the yes/no questions and receiving recommendations by email unhelpful, and one
295 parent reported watching videos of parents doing treatment unhelpful.

296 **Discussion**

297 This Phase I trial showed that, after 6 months of use, iLidcombe is a safe program for parents to
298 use with their child, with no suggestion of any psychologically adverse impact on children. This is
299 consistent with safety data when the treatment is presented face-to-face by an SLP (de Sonnevile-
300 Koedoot et al. 2015; Johnson et al., 2024; Woods et al., 2002). Survey information from parents
301 about iLidcombe was mostly positive. Parent compliance with the program was encouraging, with
302 14 of the parents who began the trial completing the 15 core training modules, and nine of them
303 providing pre-treatment and 6-months severity rating and satisfaction with communication scores.

304 However, it is not known how regularly the parents engaged with the treatment procedures of
305 iLidcombe with their children during everyday life.

306 The Lidcombe Program is designed to attain no stuttering or nearly no stuttering, and there was
307 some indication that, without any input from a live SLP, the program reduced children's stuttering
308 severity with a corresponding increase of parent satisfaction with children's everyday
309 communication. However, the study was not designed to determine whether any of those observed
310 changes were attributable to iLidcombe rather than to natural recovery. The most recent Lidcombe
311 Program clinical trial (Donaghy et al., 2020) involved a mean of 31 weeks to reach Stage 2 for 55
312 children, yet here, only one child reached Stage 2 after 24 weeks of iLidcombe access. However,
313 based on the data in Figure 2, many more of the children in the trial may eventually have reached
314 Stage 2. Standard Lidcombe Program procedures conducted by an SLP are based on scheduled
315 weekly clinical consultations of around 1 hour. Clinical research data ($N = 995$) show that a median
316 of 17 clinical weekly consultations is required (Onslow, 2025) to reach Stage 2. The iLidcombe
317 model obviates that service delivery format in a fashion that the present participants seemed to have
318 found acceptable. Although not all parents responded to the 6-month survey, it seems that those
319 who responded liked accessing iLidcombe in their own time—often as this suited their lifestyles—
320 without needing to travel to a clinic. The format enabled them to involve a partner in the treatment,
321 which is not typically an option when attending clinic appointments with an SLP. However, we
322 need to acknowledge that this may have been a biased sample and that those who elected not to
323 complete the survey may have been those who did not find it useful.

324 Another advantage of the iLidcombe treatment format is that it eliminates therapist drift (Waller,
325 2009), which is when a clinician departs from delivering a treatment exactly the way it was
326 designed and manualized. Therapist drift can occur intentionally or unintentionally, and it may
327 involve altering or omitting core treatment components, applying techniques inconsistently, or
328 adapting a treatment to personal style or perceived client needs. Therapist drift may occur for many
329 reasons, such as clinical time constraints, fatigue, and burnout. There is some evidence that it is a

330 negative influence during face-to-face delivery of the Lidcombe Program (Carr-Swift et al., 2011;
331 O'Brian et al., 2013; Swift et al., 2016). However, iLidcombe will deliver the same treatment, that
332 has been designed by an expert Lidcombe Program team, consistently over time. This aspect of
333 iLidcombe could be particularly useful for inexperienced SLPs to use as a guide when treating
334 children face-to-face.

335 Even though the present Phase I trial showed potential signs of efficacy, it is unrealistic to
336 project that iLidcombe will prove to be a suitable and efficacious treatment for all parents and
337 children who require Lidcombe Program treatment. As such, one potential contribution of this line
338 of work might lie in future development of guidelines for a stepped care model of early stuttering
339 intervention. The stepped-care model (Bower & Gilbody, 2005) provides, in the first instance, the
340 simplest and most cost-efficient method of health care that is efficacious, and then progressively
341 escalates clients to more resource-intensive, and hence more costly, models of health care should
342 they require it. Adoption of an iLidcombe stepped-care model by speech-language pathology
343 associations worldwide could be a significant and transformative change to practice and policy for
344 early stuttering treatment. The potential economic benefits of standalone treatments for stuttering in
345 a stepped-care model are highlighted by iGlebe, which is a treatment for the anxiety of adults who
346 stutter that was developed by the present team. iGlebe has been publicly available cost-free since
347 June 2020 on the Australian Stuttering research Centre website (<https://iglebe.asrc.edu.au>). At the
348 time of writing, 2,749 users from 76 countries have saved an estimated \$A5.4M (\$US3.6M) in the
349 direct cost of illness, based on an Australian clinical psychology consultation rate of \$A280
350 (\$US185) per hour.

351 The promising results of this Phase I trial provide a roadmap for further clinical trial
352 development, the first of which would be a Phase II trial to provide an estimate of effect sizes to
353 prime subsequent Phase III randomized trials. Such trials would compare iLidcombe with standard
354 practice involving an SLP, or they would compare iLidcombe to no-treatment controls. The latter
355 would account for potentially confounding variables such as participant selection

356 bias, natural recovery, and parent attention to speech. Subsequently, Phase IV trials would explore
357 the rollout of iLidcombe to clinical communities globally, with eventual translations into other
358 languages besides English. Future development of iLidcombe will benefit from incorporation of
359 emerging developments in AI technology, which could involve a clinical interface of avatar
360 clinicians to engage with parents, using natural language processing to provide guidance through
361 treatment. That development could use emerging state-of-the-art developments in stuttering
362 detection (Barrett et al., 2022), potentially integrating video-based facial micro-expression analysis
363 of children (Ben et al., 2021; Wang et al., 2021) that could operate from the user's webcam
364 (Baltrušaitis et al., 2016). The current version of iLidcombe does not require any engagement of
365 children; however, facial analysis of children would require video capture of their speech.
366 Conceivably, that addition would provide the benefit of completely objectifying the iLidcombe
367 treatment process by removing its reliance on parent severity ratings.

368 Early stuttering is a global health problem with a significant quality-of-life impact and cost of
369 illness burden. The global speech-language pathology workforce is not equipped to deal with a
370 disorder of such prevalence, where most children who stutter live in countries that have limited
371 speech-language pathology services. The iLidcombe research project foreshadows a means to
372 prevent this cost of illness by providing early stuttering intervention through global access to
373 treatment. The projected long-term outcome of this research could be effective, cost-free, automated
374 early stuttering intervention available to families globally who have internet access, regardless of
375 their location or their socioeconomic status.

376

377

378 **Acknowledgements**

379 The authors would also like to acknowledge Damien Liu-Brennan for his scientific
380 copyediting contribution to this publication.

381

382

Data Availability Statement

383

The datasets generated during and/or analyzed during the current study are available from the

384

corresponding author on reasonable request.

385

386

Declaration of Interest Statement

387

The author reports no conflict of interest.

388

References

- 389 Achenbach, T. M., & Rescorla, L. A. (2001). *Child Behavior Checklist for Ages 6-18 (CBCL/6-18,*
390 *ASEBA CBCL/6-18)* [Database record]. APA PsycTests.
391 <https://doi.org/https://doi.org/10.1037/t47452-000>
- 392 Alateras, C., O'Brian, S., Onslow, M., Hearne, A., Carey, B., Menzies, R., Packman, A., & Lowe,
393 R. (2025). *The Development of Stand-alone eHealth Treatments: iCamperdown*. Manuscript
394 submitted for publication.
- 395 Ambrose, N. G., & Yairi, E. (1999). Normative disfluency data for early childhood
396 stuttering. *Journal of Speech, Language, and Hearing Research, 42*(4), 895–909.
397 <https://doi.org/10.1044/jslhr.4204.895>
- 398 Baltrušaitis, T., Robinson, P., & Morency, L. -P. (2016, March). Openface: An open source facial
399 behavior analysis toolkit. In *2016 IEEE Winter Conference on Applications of Computer Vision*
400 *(WACV)* (pp. 1–10). IEEE. <https://doi.org/10.1109/WACV.2016.7477553>
- 401 Barrett, L., Hu, J., & Howell, P. (2022). Systematic review of machine learning approaches for
402 detecting developmental stuttering. *IEEE/ACM Transactions on Audio, Speech, and Language*
403 *Processing, 30*, 1160–1172. <https://doi.org/10.1109/TASLP.2022.3155295>
- 404 Ben, X., Ren, Y., Zhang, J., Wang, S. -J., Kpalma, K., & Meng, W. (2021). Video-based facial
405 micro-expression analysis: A survey of datasets, features and algorithms. *IEEE Transactions on*
406 *Pattern Analysis and Machine Intelligence, 44*(9), 5826–5846.
407 <https://doi.org/10.1109/TPAMI.2021.3067464>
- 408 Berchiatti, M., Badenes-Ribera, L., Ferrer, A., Longobardi, C., & Gastaldi, F. G. M. (2020). School
409 adjustment in children who stutter: The quality of the student-teacher relationship, peer
410 relationships, and children's academic and behavioral competence. *Children and Youth Services*
411 *Review, 116*(1), Article 105226. <http://dx.doi.org/10.1016/j.chilyouth.2020.105226>

- 412 Bernard, R., Hofslundsengen, H., & orbury, C. F. (2022). Anxiety and depression symptoms in
 413 children and adolescents who stutter: A Systematic Review and Meta-Analysis. *Journal of*
 414 *Speech, Language, and Hearing Research*, *65*(2), 624–644.
 415 https://doi.org/10.1044/2021_JSLHR-21-00236
- 416 Bower, P., & Gilbody, S. (2005). Stepped care in psychological therapies: Access, effectiveness,
 417 and efficiency. *BJPsych*, *186*, 11–17. <https://doi.org/10.1192/bjp.186.1.11>
- 418 Boyce, J. O., Jackson, V. E., van Reyk, O., Parker, R., Vogel, A. P., Eising, E., Horton, S. E.,
 419 Gillespie, N. A., Scheffer, I. E., Amor, D. J., Hildebrand, M. S., Fisher, S. E., Martin, N. G.,
 420 Reilly, S., Bahlo, M., & Morgan, A. T. (2022). Self-reported impact of developmental stuttering
 421 across the lifespan. *Developmental Medicine and Child Neurology*, *64*(10), 1297–1306.
 422 <https://doi.org/10.1111/dmcn.15211>
- 423 Boyle, C. A., Decoufle, P., & Yeargin-Allsopp, M. (1994). Prevalence and health impact of
 424 developmental disabilities in US children. *Pediatrics*, *93*(3), 399–403.
 425 <https://doi.org/10.1542/peds.93.3.399>
- 426 Boyle, M. P., & Cheyne, M. R. (2024). Major discrimination due to stuttering and its association
 427 with quality of life. *Journal of Fluency Disorders*, *80*, Article 106051.
 428 <https://doi.org/10.1016/j.jfludis.2024.106051>
- 429 Briley, P. M., & Jacobs, M. M. (2025). Socioecological determinants of speech evaluation and
 430 treatment among children who stutter. *American Journal of Speech-Language Pathology*, *34*(2),
 431 520–534. https://doi.org/10.1044/2024_ajslp-24-00483
- 432 Briley, P. M., O’Brien, K., & Ellis, C. (2019). Behavioral, emotional, and social well-being in
 433 children who stutter: Evidence from the National Health Interview Survey. *Journal of*
 434 *Developmental and Physical Disabilities*, *31*(1), 39–53. [https://doi.org/10.1007/S10882-018-](https://doi.org/10.1007/S10882-018-9625-X)
 435 [9625-X](https://doi.org/10.1007/S10882-018-9625-X)

A PHASE I TRIAL OF iLIDCOMBE

- 437 Caldera, A. V., Wickremasinghe, R., Munasinghe, T. U., Perera, K. M. N., Muttiah, N.,
438 Tilakaratne, D., Peiris, M. K. R. R., Thamilchelvan, E., Sooriyaarachchi, C., Nasma, M. N. and
439 Manamperige, R. M. (2023). Availability of rehabilitation services for communication disorders
440 in Sri Lanka: a cross-sectional survey. *BMJ Open*, *13*(4), Article e071620.
441 <https://doi.org/10.1136/bmjopen-2023-071620>
- 442 Carr Swift, M., O'Brian, S., Hewat, S., Onslow, M., Packman, A., & Menzies, R. (2011).
443 Investigating parent delivery of the Lidcombe Program. *International Journal of Speech*
444 *Language Pathology*, *13*(4), 308–316. <https://doi.org/10.3109/17549507.2011.550692>
- 445 Currie, S. L., McGrath, P. J., & Day, V. (2010). Development and usability of an online CBT
446 program for symptoms of moderate depression, anxiety, and stress in post-secondary
447 students. *Computers in Human Behavior*, *26*(6), 1419–1426.
448 <https://doi.org/10.1016/j.chb.2010.04.020>
- 449 de Sonnevile-Koedoot, C., Stolk, E., Rietveld, T., & Franken, M. -C. (2015). Direct versus indirect
450 treatment for preschool children who stutter: The RESTART randomized trial. *PLoS One*, *10*,
451 Article e0133758. <https://doi.org/10.1371/journal.pone.0133758>
- 452 Donaghy, M., O'Brian, S., Onslow, M., Lowe, R., Jones, M. & Menzies, R. G. (2020). Verbal
453 contingencies in the Lidcombe Program: A noninferiority trial. *Journal of Speech, Language,*
454 *and Hearing Research*, *63*(10), 3419–343. https://doi.org/10.1044/2020_jslhr-20-00155
- 455 Erickson, S., Block, S., Menzies, R., Onslow, M., O'Brian, S., & Packman, A. (2016). Standalone
456 Internet speech restructuring treatment for adults who stutter: A Phase I study. *International*
457 *Journal of Speech-Language Pathology*, *18*(4), 329–340.
458 <https://doi.org/10.3109/17549507.2015.1101156>
- 459
- 460

A PHASE I TRIAL OF iLIDCOMBE

- 461 Erickson, S., Block, S., Menzies, R., Onslow, M., O'Brian, S., & Packman, A. (2012). Stand-alone
462 Internet speech restructuring treatment for adults who stutter: A pilot study. *Journal of Clinical*
463 *Practice in Speech-Language Pathology*, 14(3), 118–123.
464 <https://doi.org/10.3109/17549507.2015.1101156>
- 465 Erickson, S., Bridgman, K., & Furlong, L. (2022). Australian speech-language pathologists'
466 experiences and perceptions of working with children who stutter: A qualitative study. *Journal*
467 *of Fluency Disorders*, 75, Article 105944. <https://doi.org/10.1016/j.jfludis.2022.105944>
- 468 Gerlach, H., Totty, E., Subramanian, A., & Zebrowski, P. (2018). Stuttering and labor market
469 outcomes in the United States. *Journal of Speech, Language, and Hearing Research*, 61(7),
470 1649–1663. https://doi.org/10.1044/2018_JSLHR-S-17-0353
- 471 Gunn A, Menzies RG, Onslow M, O'Brian S, Packman A, Lowe R, Jones M. (2019). Phase I trial of
472 a standalone internet social anxiety treatment for adolescents who stutter: iBroadway.
473 *International Journal of Language & Communication Disorders*, 54(6), 927–
474 939. <https://doi.org/10.1111/1460-6984.12496>
- 475 Helgadóttir, F. D., Menzies, R. G., Onslow, M., Packman, A., & Brian, S. O. (2009). Online CBT
476 II: A Phase I Trial of a Standalone, Online CBT Treatment Program for Social Anxiety in
477 Stuttering. *Behavior Change*, 26(4), 254–270. <https://doi.org/10.1375/behc.26.4.254>
- 478 I CAN, & Royal College of Speech and Language Therapists. (2018, March). *Bercow: Ten Years*
479 *on*. [http://www.bercow10yearson.com/wp-content/uploads/2018/03/337644-ICAN-Bercow-](http://www.bercow10yearson.com/wp-content/uploads/2018/03/337644-ICAN-Bercow-Report-WEB.pdf)
480 [Report-WEB.pdf](http://www.bercow10yearson.com/wp-content/uploads/2018/03/337644-ICAN-Bercow-Report-WEB.pdf)
- 481 Iverach, L., Jones, M., McLellan, L. F., Lyneham, H. J., Menzies, R. G., Onslow, M. & Rapee, R.
482 M. (2016). Prevalence of anxiety disorders among children who stutter. *Journal of Fluency*
483 *Disorders*, 49, 13–28. <https://doi.org/10.1016/j.jfludis.2016.07.002>

- 484 Jacobs, M., Gerlach-Houck, H., & Briley, P. (2025). Differential impacts of anticipated success on
 485 employment outcomes among adults who stutter. *American Journal of Speech-Language*
 486 *Pathology*, 34(1), 246–260. https://doi.org/10.1044/2024_AJSLP-24-00202
- 487 Johnson, G., Onslow, M., Carey, B., Jones, M., & Kefalianos, E. (2024). Lidcombe Program
 488 telehealth treatment for children 6–12 years of age: A Phase II trial. *Journal of Fluency*
 489 *Disorders*, 80, Article 106057. <https://doi.org/10.1016/j.jfludis.2024.106057>
- 490 Karimi, H., Onslow, M., Jones, M., O’Brian, S., Packman, A., Menzies, R., Reilly, S., Sommer, M.
 491 & Jelčić Jakšić, S. (2018). The Satisfaction with Communication in Everyday Speaking
 492 Situations (SCESS) scale: An overarching outcome measure of treatment effect. *Journal of*
 493 *Fluency Disorders*, 58, 77–85. <https://doi.org/10.1016/j.jfludis.2018.10.002>
- 494 Lake, T. P., Blanchet, P. G., Levonyan Radloff, T., & Klonsky, B. G. (2009). Undergraduate and
 495 graduate students’ perceptions of an instructor who stutters. *Contemporary Issues in*
 496 *Communication Science and Disorders*, 36, 26–35. https://doi.org/10.1044/cicsd_36_S_26
- 497 Lowe, R., Jelčić Jakšić, S., Onslow, M., O’Brian, S., Vanryckeghem, M., Millard, S., Kelman, E.,
 498 Block, S., Franken, M. -C., Van Eerdenbrugh, S., Menzies, R., Shenker, R., Byrd, C., Bosshardt,
 499 H. -G., del Gado, F., & Lim, V. (2021). Contemporary issues with stuttering: The Fourth Croatia
 500 Stuttering Symposium. *Journal of Fluency Disorders*, 70, Article 105844.
 501 <https://doi.org/10.1016/j.jfludis.2021.105844>
- 502 Månsson, H. (2000). Childhood stuttering: Incidence and development. *Journal of Fluency*
 503 *Disorders*, 25(1), 47–57. [https://doi.org/10.1016/S0094-730X\(99\)00023-6](https://doi.org/10.1016/S0094-730X(99)00023-6)
- 504 McAllister, J. (2016). Behavioural, emotional and social development of children who stutter.
 505 *Journal of Fluency Disorders*, 50, 23–32. <https://doi.org/10.1016/j.jfludis.2016.09.003>
- 506 McAllister, J., Collier, J., & Shepstone, L. (2012). The impact of adolescent stuttering on
 507 educational and employment outcomes: Evidence from a birth cohort study. *Journal of Fluency*
 508 *Disorders*, 37(2), 106–121. <https://doi.org/10.1016/j.jfludis.2012.01.002>

A PHASE I TRIAL OF iLIDCOMBE

- 509 McGill, N., McLeod, S., Crowe, K., Wang, C., & Hopf, S. C. (2021). Waiting lists and
510 prioritization of children for services: Speech-language pathologists' perspectives. *Journal of*
511 *Communication Disorders*, 91, Article 106099. <https://doi.org/10.1016/j.jcomdis.2021.106099>
- 512 Menzies, R., O'Brian, S., Lowe, R., Packman, A., & Onslow, M. (2016). International Phase II
513 clinical trial of CBTPsych: A standalone Internet social anxiety treatment for adults who stutter.
514 *Journal of Fluency Disorders*, 48, 35–43. <https://doi.org/10.1016/j.jfludis.2016.06.002>
- 515 Menzies, R., Packman, A., Onslow, M., O'Brian, S., Jones, M. & Helgadóttir, F. J. (2019). In-clinic
516 and standalone Internet CBT treatment for social anxiety in stuttering: A randomized trial of
517 iGlebe. *Journal of Speech, Language and Hearing Research*, 62(6), 1614–1624.
518 https://doi.org/10.1044/2019_JSLHR-S-18-0340
- 519 Norman, A., Lowe, R., Onslow, M., O'Brian, S., Packman, A., Menzies, R., & Schroeder, L.
520 (2023). Cost of illness and health-related quality of life for stuttering: Two systematic
521 reviews. *Journal of Speech, Language, and Hearing Research*, 66(11), 4414–4431.
522 https://doi.org/10.1044/2023_JSLHR-23-00072
- 523 Obigbesan, O., Graham, K., & Benzies, K. M. (2024). Software Testing of eHealth Interventions:
524 Existing Practices and the Future of an Iterative Strategy. *JMIR Nursing*, 7, Article e56585.
525 <https://doi.org/10.2196/56585>
- 526 O'Brian, S., Iverach, L., Jones, M., Onslow, M., Packman, A., & Menzies, R. (2013). Effectiveness
527 of the Lidcombe Program for early stuttering in Australian community clinics. *International*
528 *Journal of Speech-Language Pathology*, 15(6), 593–603.
529 <https://doi.org/10.3109/17549507.2013.783112>
- 530 O'Brian, S., Jones, M., Packman, A., Menzies, R., & Onslow, M. (2011). Stuttering severity and
531 educational attainment. *Journal of Fluency Disorders*, 36(2), 86–92.
532 <https://doi.org/10.1016/j.jfludis.2011.02.006>

A PHASE I TRIAL OF iLIDCOMBE

- 533 Onslow, M. (2025, October). *Stuttering and its clinical management: Twelve lectures*. Retrieved
534 December 4, 2025, from <https://www.uts.edu.au/asrc/resources>
- 535 Onslow, M., Webber, M., Harrison, E., Arnott, S., Bridgman, K., Carey, B., Sheedy, S., O’Brian,
536 S., MacMillan, V., Lloyd, W., Santayana, G., Hodes, G., Smith, K., and Hearne, A. (2025). *The*
537 *Lidcombe Program Treatment Guide*. Retrieved September 09, 2025, from
538 <https://www.uts.edu.au/asrc/resources>
- 539 Reilly, S., Onslow, M., Packman, A., Cini, E., Conway, L., Ukoumunne, O. C., Bavin, E., L., Prior,
540 M., Eadie, P., Block, S., & Wake, M. (2013). Natural history of stuttering to 4 years of age: A
541 prospective community-based study. *Pediatrics*, *132*(3), 460–467.
542 <https://doi.org/10.1542/peds.2012-3067>
- 543 Senate Community Affairs Committee Secretariat (2014, September). *Prevalence of different types*
544 *of speech, language and communication disorders and speech pathology services in Australia*.
545 Commonwealth of Australia. [https://www.aph.gov.au/-](https://www.aph.gov.au/-/media/Committees/Senate/committee/clac_ctte/speech_pathology/report/report.pdf)
546 [/media/Committees/Senate/committee/clac_ctte/speech_pathology/report/report.pdf](https://www.aph.gov.au/-/media/Committees/Senate/committee/clac_ctte/speech_pathology/report/report.pdf)
- 547 Sjøstrand, Å., Kefalianos, E., Hofslundsengen, H., Guttormsen, L. S., Kirmess, M., Lervåg, A.,
548 Hulme, C., & Bottegaard Næss, K. -A. (2021). Non-pharmacological interventions for stuttering
549 in children six years and younger. *Cochrane Database of Systematic Reviews*, *9*, Article
550 CD013489. <https://doi.org/10.1002/14651858.CD013489.pub2>
- 551 Swift, M. C., Jones, M., O’Brian, S., Onslow, M., Packman, A., & Menzies, R. (2016). Parent
552 verbal contingencies during the Lidcombe Program: Observations and statistical modeling of the
553 treatment process. *Journal of Fluency Disorders*, *47*, 13–26.
554 <https://doi.org/10.1016/j.jfludis.2015.12.002>
- 555
- 556

- 557 Thornton, L., Gardner, L. A., Osman, B., Green, O., Champion, K. E., Bryant, Z., Teesson, M.,
 558 Kay-Lambkin, F., & Chapman, C. (2021). A Multiple Health Behavior Change, Self-Monitoring
 559 Mobile App for Adolescents: Development and Usability Study of the Health4Life App. *JMIR*
 560 *Formative Research*, 5(4), e25513. <https://doi.org/10.2196/25513>
- 561 Tığrak, T. K., Kayıkcı, M. E. K., Kirazlı, M. Ç., & Tığrak, A. (2020). Emotional and behavioural
 562 problems of children and adolescents who stutter: Comparison with typically developing
 563 peers. *Logopedics Phoniatrics Vocology*, 46(4), 186–192.
 564 <https://doi.org/10.1080/14015439.2020.1855472>
- 565 United Nations (2018, May 17). *World urbanization prospects: The 2018 revision*.
 566 <https://www.un.org/en/academic-impact/united-nations-projects-increase-worlds-urban->
 567 [population](https://www.un.org/en/academic-impact/united-nations-projects-increase-worlds-urban-population)
- 568 Van Eerdenbrugh, S., Packman, A., Onslow, M., O'Brian, S., & Menzies, R. (2016). Development
 569 of an Internet Version of the Lidcombe Program of Early Stuttering Intervention: A Trial of Part
 570 1. *International Journal of Speech-Language Pathology*, 20(2), 216–225.
 571 <https://doi.org/10.1080/17549507.2016.1257653>
- 572 Waller, G. (2009). Evidence-based treatment and therapist drift. *Behaviour Research and Therapy*,
 573 47(2), 119–127. <https://doi.org/10.1016/j.brat.2008.10.018>
- 574 Wang, J., Chai, W., Venkatachalapathy, A., Tan, K. L., Haghghat, A., & Velipasalar, S. (2021). A
 575 survey on driver behavior analysis from in-vehicle cameras. *IEEE Transactions on Intelligent*
 576 *Transportation Systems*, 23(8), 10186–10209. <https://doi.org/10.1109/TITS.2021.3126231>
- 577 Williams, D. E., Melrose, B. M., & Woods, C. L. (1969). The relationship between stuttering and
 578 academic achievement in children. *Journal of Communication Disorders*, 2(2), 87–98.
 579 [https://doi.org/10.1016/0021-9924\(69\)90032-X](https://doi.org/10.1016/0021-9924(69)90032-X)

A PHASE I TRIAL OF iLIDCOMBE

- 580 Woods, S., Shearsby, J., Onslow, M., & Burnham, D. (2002). Psychological impact of the
581 Lidcombe Program of early stuttering intervention. *International Journal of Language and*
582 *Communication Disorders*, 37(1), 31–40. <https://doi.org/10.1080/13682820110096670>
- 583 Yairi, E. (1983). The onset of stuttering in two- and three-year-old children: A preliminary report.
584 *Journal of Speech and Hearing Disorders*, 48(2), 171–177.
585 <https://doi.org/10.1044/jshd.4802.171>

586 **Captions:**

587 Table 1. Safety screening survey


588 Table 1. Safety screening survey

1	Unusual displays of low mood (e.g., excessive tearfulness or distress)
2	Easily frustrated
3	Unusual displays of anger
4	Aggressive behaviour toward self or other (e.g., kicking, hitting, biting)
5	Negative reactions to the treatment (e.g., your child says “don’t tell me to do that”, or “don’t talk like that”, or “stop saying that”)
6	Refusing to do the treatment
7	Refusing to talk or a significant reduction in talking
8	Withdrawing from interacting or playing with other children
9	A deteriorating relationship between you and your child

589


590

591 Figure 1. Trial flow chart. SCESS = parent satisfaction with the child’s communication in everyday
 592 speaking situations




593

594 Figure 2. Parent reported typical stuttering severity rating



595

596 Figure 3. Parent-reported satisfaction with the child's communication in everyday speaking
597 situations.



598